(PR-inside.com) TUSTIN, CA -- (Marketwire) -- 10/04/11 -- Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced the launch of a national marketing campaign to drive awareness and adoption of Onko-Sure® for its FDA cleared indication in treatment monitoring and recurrence monitoring of colorectal cancer. This comprehensive campaign includes online and print marketing, advertising, and public relations aimed at key constituencies including doctors, patients, and labs. The campaign will support three new sales people hired by Radient for domestic U.S. sales. Radient will look to ..
More...
More...